Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TB PROGNOSIS

Financiado

Cerrado

A progress of tuberculosis and HIV tuberculosis treatment assessed by fingerprin...

A progress of tuberculosis and HIV tuberculosis treatment assessed by fingerprinting of small molecule biomarkers in patients from Eastern Europe A dramatically high incidence of multidrug-resistant (MDR) and extended drug resistant (XDR) tuberculosis (TB) was reported in WHO European Region. Countries in Eastern Europe still fail to control TB and in, for example, Ukraine,... ver más

31/03/2017

UMEA UNIVERSITET

133K€

Presupuesto del proyecto: 133K€

Líder del proyecto

UMEA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UMEA UNIVERSITET

0.00€ | Lider

FUNDACIO INSTITUT D'INVESTIG...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STOOL4TB Evaluating a new stool based qPCR for diagnosis of tuberculo... 348K€ Cerrado

PCI2023-143397 Inmunidad, infección e inmunoterapia 100K€ Cerrado

DEMO-NOPERSIST Demonstration of NOPERSIST results leading to novel validat... 691K€ Cerrado

RTI2018-094399-A-I00 DETERMINANTES GENETICOS DE LA ESPECIFICIDAD DE HUESPED DEL C... 157K€ Cerrado

BES-2017-079656 TUBERCULOSIS MULTIRRESISTENTE: DE LA BIOLOGIA AL DIAGNOSTICO 93K€ Cerrado

ADVANTAGE ADvanced Validation of A Novel TB Active disease diagnostic... 4M€ Cerrado

Líder del proyecto

UMEA UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 133K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto A dramatically high incidence of multidrug-resistant (MDR) and extended drug resistant (XDR) tuberculosis (TB) was reported in WHO European Region. Countries in Eastern Europe still fail to control TB and in, for example, Ukraine, a number of new TB cases is as high as 100-299 per 100 000 (data for 2010). TB is often accompanied by HIV on this territory. In EU countries, patients with MDR and XDR-TB recover with the efficiency of only 32%. For successful control of TB, quick diagnosis is among most important factors. In low-income countries, TB diagnostics is restricted mainly to clinical manifestations and sputum smear microscopy. TB clinical symptoms are often obscured in HIV positive individuals and sputum smear test detects only up to 60% of TB cases. Modern more efficient methods are not affordable. Furthermore, there are few tools to judge the efficiency of a certain therapy in already confirmed TB cases. We hypothesize that cheaper and quicker detection of TB is possible as well as assessment of the treatment progress over the time. It could be done through measurement of small molecule biomarkers in body fluids of the patients. A network has been created between Umea University, Sweden, Metchnikov’s University/TB Clinics, Ukraine and University Hospital Germans Trias i Pujol, Spain that has access to a modern metabolomics facility and an extensive work experience with TB and chemical analysis of biomedical samples. We propose to collect samples from Ukrainian TB and HIV/TB patients under treatment and analyze them with several chromatographic methods in order to detect relevant biomarkers. We plan also to genotype M.tuberculosis isolates from these patients, monitor possible antibiotic resistance development and evaluate the host response. An array of these methods will help to get a detailed and dynamic clinical description of the cases and assign certain small molecules levels to respective events during treatment of TB, MDR-TB and HIV/TB co-infection.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores